Experienced in Medulloblastoma

Dr. Naoko Takebe

Hematology Oncology
Ou Health Partners Inc
900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Medulloblastoma
Ou Health Partners Inc
900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Naoko Takebe is a Hematologist Oncology provider in Oklahoma City, Oklahoma. Dr. Takebe is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her top areas of expertise are Chondrosarcoma, Alveolar Soft Part Sarcoma, Adult Soft Tissue Sarcoma, and Glioma.

Her clinical research consists of co-authoring 122 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Medulloblastoma.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
O U Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

OU HEALTH PARTNERS INC
900 Ne 10th St, Ouhp Family Medicine, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Elimusertib, Gemcitabine Hydrochloride, BAY 1895344
Study Phase: Phase 1
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Z-Endoxifen
Study Phase: Phase 1
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: November 28, 2025
Intervention Type: Drug
Study Drugs: Bortezomib, Clofarabine
Study Phase: Phase 1
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Drug, Other
Study Drugs: Docetaxel, PI3Kbeta Inhibitor AZD8186
Study Phase: Phase 1
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Withdrawn
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

121 Total Publications

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Journal: JCO precision oncology
Published: October 09, 2025
Similar Doctors
Experienced in Medulloblastoma
Dr. Jehanzeb Riaz
Hematology Oncology | Oncology | Hematology
Experienced in Medulloblastoma
Dr. Jehanzeb Riaz
Hematology Oncology | Oncology | Hematology

Ou Health Partners Inc

900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-4311
Languages Spoken:
English, Filipino, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Jehanzeb Riaz is a Hematologist Oncology specialist and an Oncologist in Oklahoma City, Oklahoma. Dr. Riaz is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Riaz is currently accepting new patients.

Experienced in Medulloblastoma
Dr. Erin E. Ezzell
Hematology Oncology | Hematology | Oncology
Experienced in Medulloblastoma
Dr. Erin E. Ezzell
Hematology Oncology | Hematology | Oncology

Ou Health Partners Inc

901 N Porter Ave, 
Norman, OK 
 (17.5 miles away)
405-515-4644
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Erin Ezzell is a Hematologist Oncology specialist and a Hematologist in Norman, Oklahoma. Dr. Ezzell is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Breast Cancer, and Paget Disease of the Breast. Dr. Ezzell is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Takebe's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile